Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare To Cover At-Home Test To Detect Organ Rejection After Kidney Transplant Surgery

Executive Summary

US Medicare has issued a local coverage determination (LCD) for NephroSant’s QSant test, which uses artificial intelligence to score a patient’s likelihood of experiencing organ rejection after transplant. Early detection of rejection could be a game-changer for organ recipients.

You may also be interested in...



Organ Transplant Surgery Has Advanced – Organ Storage Should Too

The CEO of Organ Recovery Systems tells Medtech Insight that the latest technology in organ preservation and transport could mean greater access to viable organs and more saved lives.

Proposed ESRD Reimbursement Changes Look To Improve Equity In Care For Patients With Chronic Kidney Disease

Changes to the mandatory payment model now used by the US Centers for Medicare & Medicaid Services (CMS) for kidney disease would encourage facilities to provide treatment to lower income patients.

Potential Pump Malfunction Results In Class I Recall For LifeSPARC Circulatory System

The US FDA has labelled a recall of several hundred components of the LifeSPARC circulatory support system from LivaNova as class I, the agency’s most serious recall designation.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT144550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel